Search research articles
Contact Us
Filters
Showing results (31-40 of 46) with videos related to
Page
of 5
Sort By:
Molecular Cancer
|
June 8, 2010
Anti-angiogenic SPARC peptides inhibit progression of neuroblastoma tumors
Alexandre Chlenski, Lisa J Guerrero, Radhika Peddinti, et al.
Pediatric Blood & Cancer
|
December 8, 2011
Sorafenib inhibits neuroblastoma cell proliferation and signaling, blocks angiogenesis, and impairs tumor growth
Nisha C Kakodkar, Radhika R Peddinti, Yufeng Tian, et al.
Oncotarget
|
October 25, 2016
Secreted protein acidic and rich in cysteine (SPARC) induces lipotoxicity in neuroblastoma by regulating transport of albumin complexed with fatty acids
Alexandre Chlenski, Marija Dobratic, Helen R Salwen, et al.
Cancer Research
|
December 25, 2002
SPARC is a key Schwannian-derived inhibitor controlling neuroblastoma tumor angiogenesis
Alexandre Chlenski, Shuqing Liu, Susan E Crawford, et al.
The Journal of Laboratory and Clinical Medicine
|
March 1, 1989
Characterization of a novel myeloma cell line, MM.1
R E Goldman-Leikin, H R Salwen, C V Herst, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 31, 2000
MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN
S L Cohn, W B London, D Huang, et al.
Oncogene
|
January 23, 2004
MYCN-mediated regulation of the MRP1 promoter in human neuroblastoma
Chitra F Manohar, James A Bray, Helen R Salwen, et al.
Pediatric Blood & Cancer
|
September 23, 2010
The quinoxaline anti-tumor agent (R+)XK469 inhibits neuroblastoma tumor growth
Nisha C Kakodkar, Radhika Peddinti, Morris Kletzel, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology
|
March 1, 1987
Establishment and characterization of a neuroendocrine skin carcinoma cell line
S T Rosen, V E Gould, H R Salwen, et al.
Plos One
|
September 28, 2011
Secreted protein acidic and rich in cysteine is a matrix scavenger chaperone
Alexandre Chlenski, Lisa J Guerrero, Helen R Salwen, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 46) with videos related to
Sort By:
Page
of 5
Molecular Cancer
|
June 8, 2010
Anti-angiogenic SPARC peptides inhibit progression of neuroblastoma tumors
Alexandre Chlenski, Lisa J Guerrero, Radhika Peddinti, et al.
Pediatric Blood & Cancer
|
December 8, 2011
Sorafenib inhibits neuroblastoma cell proliferation and signaling, blocks angiogenesis, and impairs tumor growth
Nisha C Kakodkar, Radhika R Peddinti, Yufeng Tian, et al.
Oncotarget
|
October 25, 2016
Secreted protein acidic and rich in cysteine (SPARC) induces lipotoxicity in neuroblastoma by regulating transport of albumin complexed with fatty acids
Alexandre Chlenski, Marija Dobratic, Helen R Salwen, et al.
Cancer Research
|
December 25, 2002
SPARC is a key Schwannian-derived inhibitor controlling neuroblastoma tumor angiogenesis
Alexandre Chlenski, Shuqing Liu, Susan E Crawford, et al.
The Journal of Laboratory and Clinical Medicine
|
March 1, 1989
Characterization of a novel myeloma cell line, MM.1
R E Goldman-Leikin, H R Salwen, C V Herst, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 31, 2000
MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN
S L Cohn, W B London, D Huang, et al.
Oncogene
|
January 23, 2004
MYCN-mediated regulation of the MRP1 promoter in human neuroblastoma
Chitra F Manohar, James A Bray, Helen R Salwen, et al.
Pediatric Blood & Cancer
|
September 23, 2010
The quinoxaline anti-tumor agent (R+)XK469 inhibits neuroblastoma tumor growth
Nisha C Kakodkar, Radhika Peddinti, Morris Kletzel, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology
|
March 1, 1987
Establishment and characterization of a neuroendocrine skin carcinoma cell line
S T Rosen, V E Gould, H R Salwen, et al.
Plos One
|
September 28, 2011
Secreted protein acidic and rich in cysteine is a matrix scavenger chaperone
Alexandre Chlenski, Lisa J Guerrero, Helen R Salwen, et al.
Page
of 5